Hantz Financial Services Inc. reduced its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,134 shares of the medical equipment provider's stock after selling 1,134 shares during the period. Hantz Financial Services Inc.'s holdings in ResMed were worth $10,093,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. True Wealth Design LLC raised its position in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after buying an additional 110 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in ResMed during the third quarter valued at $34,000. Rosenberg Matthew Hamilton acquired a new position in ResMed during the fourth quarter valued at $54,000. Capital Performance Advisors LLP acquired a new stake in ResMed during the 3rd quarter worth about $60,000. Finally, Quarry LP raised its stake in shares of ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider's stock valued at $63,000 after buying an additional 242 shares during the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.
ResMed Price Performance
Shares of RMD traded up $3.22 during trading hours on Wednesday, hitting $253.16. 931,880 shares of the stock were exchanged, compared to its average volume of 829,049. The stock's 50-day moving average price is $239.80 and its two-hundred day moving average price is $235.71. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The company has a market cap of $37.16 billion, a price-to-earnings ratio of 33.53, a price-to-earnings-growth ratio of 1.78 and a beta of 0.70. ResMed Inc. has a 12-month low of $170.56 and a 12-month high of $260.49.
Analysts Set New Price Targets
RMD has been the topic of a number of recent research reports. Piper Sandler assumed coverage on ResMed in a research note on Friday, January 10th. They issued a "neutral" rating and a $252.00 target price on the stock. Robert W. Baird lifted their target price on shares of ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Royal Bank of Canada increased their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. KeyCorp lifted their price objective on shares of ResMed from $251.00 to $266.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a research note on Thursday, January 16th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $238.40.
Read Our Latest Analysis on RMD
Insider Transactions at ResMed
In related news, Director Witte Jan De sold 796 shares of ResMed stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the sale, the director now owns 81,218 shares of the company's stock, valued at approximately $19,951,201.70. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,099 shares of company stock valued at $2,719,385. Corporate insiders own 0.71% of the company's stock.
ResMed Profile
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Articles
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
